REDHILL BIOPHARMA LTD-SP ADR (RDHL)
US7574683014 - ADR
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 85.76M 33.25% | 61.8M -27.94% | 6.53M -89.43% | 21.216M 224.90% | 38.76M 82.69% | 51.612M 33.16% | 64.974M 25.89% | |
| EBITDA YoY % growth | -54.09M 0.07% | -34.68M 35.88% | 14.622M 142.16% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -72.24M -14.89% | -42.84M 40.70% | 12.632M 129.49% | -23.256M -284.10% | -6.63M 71.49% | 2.244M 133.85% | 11.73M 422.73% | |
| Operating Margin | -84.24% | -69.32% | 193.45% | -109.62% | -17.11% | 4.35% | 18.05% | |
| EPS YoY % growth | -2,100.00 | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2022 Q2Q % growth | -0.06 99.99% | % | ||
| Q2 2022 Q2Q % growth | -200.00 66.67% | -30.60 | -169.40 | -553.59% |
| Q1 2022 Q2Q % growth | -300.00 40.00% | -234.60 | -65.40 | -27.88% |
| Q4 2021 Q2Q % growth | -500.00 28.57% | -336.60 | -163.40 | -48.54% |
| Q3 2021 Q2Q % growth | -500.00 | -210.80 | -289.20 | -137.19% |
| Q2 2021 Q2Q % growth | -600.00 -50.00% | -120.36 | -479.64 | -398.50% |
| Q1 2021 Q2Q % growth | -500.00 | -346.80 | -153.20 | -44.18% |
| Q4 2020 Q2Q % growth | -700.00 -100.00% | -247.35 | -452.65 | -183.00% |
| Q3 2020 Q2Q % growth | -500.00 -42.86% | -161.16 | -338.84 | -210.25% |
| Q2 2020 Q2Q % growth | -400.00 | -71.40 | -328.60 | -460.22% |
| Q1 2020 Q2Q % growth | -500.00 -42.86% | -248.20 | -251.80 | -101.45% |
| Q4 2019 Q2Q % growth | -350.00 | -242.25 | -107.75 | -44.48% |
| Q3 2019 Q2Q % growth | -350.00 | -410.04 | 60.04 | 14.64% |
| Q2 2019 Q2Q % growth | -400.00 | -293.76 | -106.24 | -36.17% |
| Q1 2019 Q2Q % growth | -350.00 | -275.40 | -74.60 | -27.09% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2024 Q2Q % growth | 2.572M 42.89% | % | ||
| Q4 2023 Q2Q % growth | 6.53M -48.98% | % | ||
| Q2 2023 Q2Q % growth | 1.8M -90.19% | % | ||
| Q1 2023 Q2Q % growth | 3.6M -72.52% | % | ||
| Q4 2022 Q2Q % growth | 12.8M -42.00% | % | ||
| Q3 2022 Q2Q % growth | 17.55M -18.79% | % | ||
| Q2 2022 Q2Q % growth | 18.35M -14.65% | 21.933M | -3.583M | -16.34% |
| Q1 2022 Q2Q % growth | 13.1M -36.35% | 24.786M | -11.686M | -47.15% |
| Q4 2021 Q2Q % growth | 22.07M 2.84% | 24.559M | -2.489M | -10.13% |
| Q3 2021 Q2Q % growth | 21.61M 3.20% | 25.011M | -3.401M | -13.60% |
| Q2 2021 Q2Q % growth | 21.5M 2.87% | 25.522M | -4.022M | -15.76% |
| Q1 2021 Q2Q % growth | 20.58M 1,841.51% | 23.157M | -2.577M | -11.13% |
| Q4 2020 Q2Q % growth | 21.46M 1,249.69% | 26.555M | -5.095M | -19.19% |
| Q3 2020 Q2Q % growth | 20.94M 1,395.71% | 25.879M | -4.939M | -19.08% |
| Q2 2020 Q2Q % growth | 20.9M 1,239.74% | 23.45M | -2.55M | -10.87% |
| Q1 2020 Q2Q % growth | 1.06M -39.08% | 4.466M | -3.406M | -76.27% |
| Q4 2019 Q2Q % growth | 1.59M | 2.197M | -607K | -27.63% |
| Q3 2019 Q2Q % growth | 1.4M | 1.807M | -407K | -22.52% |
| Q2 2019 Q2Q % growth | 1.56M | 2.201M | -641K | -29.12% |
| Q1 2019 Q2Q % growth | 1.74M | 2.82M | -1.08M | -38.30% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | 0% | 0% |